Soft Tissue Repair Global Market
1 EXECUTIVE SUMMARY 35
2 INTRODUCTION 40
- 2.1 KEY TAKEAWAYS 40
- 2.2 REPORT DESCRIPTION 41
- 2.3 MARKETS COVERED 43
- 2.4 STAKEHOLDERS 45
- 2.5 RESEARCH METHODOLOGY 46
- 2.5.1 MARKET SIZE ESTIMATION 47
- 2.5.2 MARKET BREAKDOWN AND DATA TRIANGULATION 50
- 2.5.3 SECONDARY SOURCES 51
- 2.5.4 PRIMARY SOURCES 52
- 2.5.5 KEY DATA POINTS FROM SECONDARY SOURCES 52
- 2.5.6 KEY DATA POINTS FROM PRIMARY SOURCES 53
- 2.5.7 ASSUMPTIONS 54
3 MARKET ANALYSIS 56
- 3.1 INTRODUCTION 56
- 3.2 MARKET SEGMENTATION 57
- 3.3 FACTORS INFLUENCING MARKET 59
- 3.3.1 DRIVERS AND OPPORTUNITIES 60
- 3.3.1.1 Increased incidents of soft tissue injuries 60
- 3.3.1.2 Rise in ageing population 61
- 3.3.1.3 Technological advancements 62
- 3.3.1.4 Increase in investments and growth in emerging markets. 63
- 3.3.2 RESTRAINS AND THREATS 64
- 3.3.2.1 Lack of awareness 64
- 3.3.2.2 Limited reimbursement 65
- 3.3.2.3 High cost of products 65
- 3.3.2.4 Strict regulations 66
- 3.3.1 DRIVERS AND OPPORTUNITIES 60
- 3.4 REGULATORY AFFAIRS 67
- 3.4.1 U.S. 67
- 3.4.2 EUROPE 68
- 3.4.3 CHINA 69
- 3.4.4 INDIA 70
- 3.4.5 JAPAN 71
- 3.4.6 AUSTRALIA 72
- 3.5 REIMBURSEMENT SCENARIO 73
- 3.6 PATENT ANALYSIS 91
- 3.7 TECHNOLOGY ADVANCEMENTS 93
- 3.7.1 IMPLANT DESIGN 93
- 3.7.2 BIOMATERIAL ADVANCEMENTS 94
- 3.8 FUNDING SCENARIO 96
- 3.9 SOFT TISSUE REPAIR PRODUCTS - DEALS 97
- 3.10 UPCOMING TECHNOLOGY AND PRODUCT LAUNCH 101
- 3.11 CLINICAL TRIALS 103
- 3.12 PORTER’S FIVE FORCE ANALYSIS 110
- 3.12.1 THREAT OF NEW ENTRANTS 111
- 3.12.2 THREAT OF SUBSTITUTES 111
- 3.12.3 BARGAINING POWER OF SUPPLIERS 112
- 3.12.4 BARGAINING POWER OF BUYERS 112
- 3.12.5 COMPETITIVE RIVALRY 113
- 3.13 SUPPLY CHAIN ANALYSIS 114
- 3.13.1 RAW MATERIAL SUPPLIER: 114
- 3.13.2 ORIGINAL EQUIPMENT MANUFACTURERS (OEM):- 116
- 3.13.3 PRODUCT MANUFACTURERS:- 116
- 3.13.4 SOFT TISSUE REPAIR PRODUCTS DISTRIBUTORS: 117
- 3.13.5 END-USERS 118
- 3.14 MARKET SHARE ANALYSIS 119
4 SOFT TISSUE REPAIR GLOBAL MARKET, BY PRODUCTS 128
- 4.1 INTRODUCTION 128
- 4.2 MESH/TISSUE PATCHES 131
- 4.2.1 SYNTHETIC MESHES 136
- 4.2.1.1 Absorbable meshes 139
- 4.2.1.2 Non-absorbable meshes 140
- 4.2.2 BIOLOGICAL MESHES 141
- 4.2.2.1 Allograft 144
- 4.2.2.2 Xenograft 146
- 4.2.1 SYNTHETIC MESHES 136
- 4.3 FIXATION DEVICES 148
- 4.3.1 SUTURE ANCHORS 153
- 4.3.2 INTERFERENCE SCREWS 155
- 4.3.3 OTHER FIXATION DEVICES 157
- 4.4 CARDIAC REPAIR DEVICES 159
- 4.4.1 HEART VALVES 164
- 4.4.1.1 Mechanical heart valves 166
- 4.4.1.2 Biological heart valves (tissue valves) 168
- 4.4.2 OTHER CARDIAC REPAIR DEVICES 170
- 4.4.1 HEART VALVES 164
- 4.5 OTHERS 173
- 4.5.1 CORNEAL TRANSPLANTATION 176
- 4.5.2 OTOLOGIC GRAFT 176
- 4.5.3 CARDIAC GRAFTS 176
- 4.5.4 TENDONS AND LIGAMENT GRAFTS 177
5 SOFT TISSUE REPAIR GLOBAL MARKET, BY SURGERY 178
- 5.1 INTRODUCTION 178
- 5.2 OPEN SURGERY 181
- 5.3 MINIMALLY INVASIVE SURGERY 185
- 5.3.1 LAPAROSCOPIC SURGERY 189
- 5.3.2 ARTHROSCOPIC SURGERY 191
- 5.3.3 CATHETER-BASED SURGERY 193
- 5.3.4 ROBOTIC SURGERY 196
6 SOFT TISSUE REPAIR GLOBAL MARKET, BY APPLICATION 198
- 6.1 INTRODUCTION 198
- 6.2 HERNIA REPAIR 202
- 6.2.1 INGUINAL HERNIA REPAIR 207
- 6.2.2 INCISIONAL HERNIA REPAIR 209
- 6.2.3 UMBILICAL HERNIA REPAIR 211
- 6.2.4 OTHER HERNIA REPAIRS 213
- 6.3 DENTAL RECONSTRUCTION 217
- 6.4 VAGINAL SLINGS 219
- 6.5 SKIN REPAIR 221
- 6.6 BREAST RECONSTRUCTION 224
- 6.7 ORTHOPEDIC 228
- 6.7.1 DURAL REPAIR 231
- 6.7.2 SPORTS MEDICINE 236
- 6.7.2.1 Anterior Cruciate Ligament (ACL) repair 242
- 6.7.2.2 Rotator cuff repair 245
- 6.7.2.3 Achilles Tendon Repair 248
- 6.7.2.4 Other repairs 251
- 6.8 CARDIAC REPAIR 254
- 6.8.1 TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) 259
- 6.8.2 MECHANICAL HEART VALVES REPLACEMENT 261
- 6.8.3 BIOLOGICAL HEART VALVE REPLACEMENT 263
- 6.8.4 ANNULOPLASTY RING 265
- 6.8.5 MITRACLIP 267
- 6.8.6 OCCLUDERS 269
- 6.8.7 STENT GRAFTS AND CARDIAC TISSUE PATCHES 271
- 6.9 OTHER SOFT TISSUE REPAIRS 273
7 SOFT TISSUE REPAIR MARKET, BY REGION 278
- 7.1 INTRODUCTION 278
- 7.2 NORTH AMERICA 281
- 7.2.1 U.S. 318
- 7.2.2 OTHERS 321
- 7.3 EUROPE 324
- 7.3.1 GERMANY 362
- 7.3.2 FRANCE 365
- 7.3.3 U.K. 368
- 7.3.4 OTHERS 371
- 7.4 ASIA-PACIFIC 374
- 7.4.1 JAPAN 412
- 7.4.2 CHINA 415
- 7.4.3 INDIA 418
- 7.4.4 OTHERS 421
- 7.5 ROW 424
- 7.5.1 BRAZIL 461
- 7.5.2 REST OF LATIN AMERICA 464
- 7.5.3 MIDDLE EAST & OTHERS 467
8 COMPETITIVE LANDSCAPE 470
- 8.1 INTRODUCTION 470
- 8.2 APPROVALS 472
- 8.3 ACQUISITIONS & MERGERS 475
- 8.4 NEW PRODUCT LAUNCHES 478
- 8.5 AGREEMENTS 480
- 8.6 OTHER STRATEGIES 481
9 MAJOR COMPANIES 482
- 9.1 ABBOTT LABORATORIES 482
- 9.1.1 OVERVIEW 482
- 9.1.2 FINANCIALS 483
- 9.1.3 PRODUCT PORTFOLIO 487
- 9.1.4 KEY DEVELOPMENTS 488
- 9.1.5 BUSINESS STRATEGY 488
- 9.1.6 SWOT ANALYSIS 489
- 9.2 ACELITY L.P. INC (ALLERGAN) 490
- 9.2.1 OVERVIEW 490
- 9.2.2 FINANCIALS 491
- 9.2.3 PRODUCT PORTFOLIO 495
- 9.2.4 KEY DEVELOPMENTS 496
- 9.2.5 BUSINESS STRATEGY 497
- 9.2.6 SWOT ANALYSIS 498
- 9.3 ARTHREX INC. 499
- 9.3.1 OVERVIEW 499
- 9.3.2 FINANCIALS 500
- 9.3.3 PRODUCT PORTFOLIO 500
- 9.3.4 KEY DEVELOPMENTS 501
- 9.3.5 BUSINESS STRATEGY 501
- 9.3.6 SWOT ANALYSIS 502
- 9.4 C.R.BARD INC. 503
- 9.4.1 OVERVIEW 503
- 9.4.2 FINANCIALS 504
- 9.4.3 PRODUCT PORTFOLIO 508
- 9.4.4 KEY DEVELOPMENTS 509
- 9.4.5 BUSINESS STRATEGY 509
- 9.4.6 SWOT ANALYSIS 510
- 9.5 EDWARDS LIFESCIENCES CORP. 511
- 9.5.1 OVERVIEW 511
- 9.5.2 FINANCIALS 512
- 9.5.3 PRODUCT PORTFOLIO 516
- 9.5.4 KEY DEVELOPMENTS 516
- 9.5.5 BUSINESS STRATEGY 518
- 9.5.6 SWOT ANALYSIS 519
- 9.6 INTEGRA LIFESCIENCES CORPORATION 520
- 9.6.1 OVERVIEW 520
- 9.6.2 FINANCIALS 521
- 9.6.3 PRODUCT PORTFOLIO 525
- 9.6.4 KEY DEVELOPMENTS 526
- 9.6.5 BUSINESS STRATEGY 527
- 9.6.6 SWOT ANALYSIS 528
- 9.7 JOHNSON & JOHNSON 529
- 9.7.1 OVERVIEW 529
- 9.7.2 FINANCIALS 530
- 9.7.3 PRODUCT PORTFOLIO 537
- 9.7.4 KEY DEVELOPMENTS 539
- 9.7.5 BUSINESS STRATEGY 540
- 9.7.6 SWOT ANALYSIS 541
- 9.8 LIVANOVA, PLC 542
- 9.8.1 OVERVIEW 542
- 9.8.2 FINANCIALS 543
- 9.8.3 PRODUCT PORTFOLIO 547
- 9.8.4 KEY DEVELOPMENTS 548
- 9.8.5 BUSINESS STRATEGY 549
- 9.8.6 SWOT ANALYSIS 550
- 9.9 MEDTRONIC, PLC 551
- 9.9.1 OVERVIEW 551
- 9.9.2 FINANCIALS 552
- 9.9.3 PRODUCT PORTFOLIO 558
- 9.9.4 KEY DEVELOPMENTS 559
- 9.9.5 BUSINESS STRATEGY 559
- 9.9.6 SWOT ANALYSIS 560
- 9.10 ORGANOGENESIS, INC. 561
- 9.10.1 OVERVIEW 561
- 9.10.2 FINANCIALS 561
- 9.10.3 PRODUCT PORTFOLIO 561
- 9.10.4 KEY DEVELOPMENTS 562
- 9.10.5 BUSINESS STRATEGY 562
- 9.10.6 SWOT ANALYSIS 563
- 9.11 SMITH & NEPHEW, PLC 564
- 9.11.1 OVERVIEW 564
- 9.11.2 FINANCIALS 565
- 9.11.3 PRODUCT PORTFOLIO 570
- 9.11.4 KEY DEVELOPMENTS 571
- 9.11.5 BUSINESS STRATEGY 572
- 9.11.6 SWOT ANALYSIS 573
- 9.12 ZIMMER BIOMET HOLDINGS, INC 574
- 9.12.1 OVERVIEW 574
- 9.12.2 FINANCIALS 575
- 9.12.3 PRODUCT PORTFOLIO 579
- 9.12.4 KEY DEVELOPMENTS 580
- 9.12.5 BUSINESS STRATEGY 580
Muscles, ligaments, tendons, fat and connective tissue constitutes soft tissue, where as Bones, cartilage and dental enamel is considered to be hard tissues. Damage to these Soft tissues are repaired by procedures that include hernia repair, cardiac repair, breast reconstruction, dental reconstruction, skin repair, etc. It does not include procedures that involve whole organ transplant and tissue regeneration and consist of products that are essential for patients suffering with soft tissue injuries and damage. With the projected rise in aged population, sports injuries and increased number of medical procedures such as hernia repair, cardiac repair, vaginal sling procedures, dental reconstruction, skin repair, etc. The market is focused on growing with newer technology and improved products. According to IQ4I analysis, the soft tissue repair global market is expected to grow at high single digit CAGR reach $21,319.7 million by 2023. Factors driving the soft tissue repair market include, increase in aging population, increase in medical procedures and sports injuries along with technology advancements and growing investment potential in emerging markets are contributing to the growth of soft tissue repair global market. Lack of awareness, limited reimbursements and high cost of procedures are hampering the market growth. Advancement of technology with its wide application areas shows that soft tissue repair market has vast opportunities in the coming years.
Soft tissue repair global market is classified based on products, surgeries, applications, and geography. The products segment is divided into four segments i.e., meshes/tissue patches, fixation devices, cardiac repair devices and others. Where, the meshes/tissue patches are further classified into synthetic meshes (absorbable meshes and non-absorbable meshes) and biological meshes (allografts tissue patches and Xenograft). The fixation devices market included products such as suture anchors, interference screws and others. The cardiac repair devices market included products such as heart valves (mechanical heart valve, biologic heart valve) and others. While, the others market includes products such as cornea, otologic grafts, cardiac grafts and tendons and ligament grafts. Soft tissue repair market based on surgery is classified into open surgery and minimally invasive surgery (laparoscopy, arthroscopy, catheter based surgery and robotic surgery).
Based on application, the soft tissue repair products are segmented into hernia repair, dental reconstruction, vaginal sling procedure, skin repair, breast reconstruction, orthopedic (dural repair and sports medicine), cardiac repair (transcatheter aortic valve replacement, mechanical heart valve replacement, biological heart valve replacement, annuloplasty ring, MitraClip, occluders, stent grafts and cardiac tissue patches).
Based on geography soft tissue repair global market is classified as North America, Europe, Asia Pacific and Rest of the world. North America accounts for the highest market share followed by Europe. The steep rise in aging population, increase in medical procedures and sports injuries along with technology advancements and growing investment potential in emerging markets are driving factors of soft tissue repair products market. However, Asian countries especially China and India are the fastest growing regions with its growing demand for soft tissue repair products.
Major players in soft tissue repair market include Edwards Lifesciences (U.S.), Medtronic PLC (Ireland), Abbott Laboratories (U.S.), Arthrex Inc (U.S.), Johnson & Johnson (U.S.), C.R. Bard Inc, (U.S.), Allergan (Lifecell) (U.S.), Smith & Nephew (U.K.), Integra Lifesciences (U.S.), Livanova (U.K.), Zimmer Biomet (U.S.), Organogenesis (U.S.), etc.
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
o U.S.
o Others
• Europe
o Germany
o U.K.
o France
o Others
• Asia-Pacific
o Japan
o China
o India
o Others
• Rest of the World (RoW)
o Brazil
o Rest of Latin America
o Middle-East and Others